Clinical trial
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients…
NCT00443872 · Parkinson's Disease and Movement Disorder Center of Boca Raton, Other · Completed
Key facts
| NCT number | NCT00443872 |
|---|---|
| Title | Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists |
| Official title | Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications |
| Acronym | AtoZ |
| Lead sponsor | Parkinson's Disease and Movement Disorder Center of Boca Raton, Other |
| Collaborators | Bausch Health Americas, Inc. Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | orally disintegrating selegiline (Zelapar) |
| Enrollment | 77 |
| Start date | Mar 1, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Mar 6, 2007 |
| Last update posted | Oct 31, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: